What is the guideline‑based treatment for chronic heart failure with reduced ejection fraction?

Treatment for Heart Failure with Reduced Ejection Fraction

All patients with chronic HFrEF should receive quadruple therapy consisting of: (1) an ARNI (sacubitril-valsartan) or ACE inhibitor, (2) an evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), (3) a mineralocorticoid receptor antagonist (MRA), and (4) an SGLT2 inhibitor (dapagliflozin or empagliflozin), initiated rapidly and titrated to target doses within 6-12 weeks. 1, 2

Core Pharmacologic Strategy: The Four Pillars

The modern approach to HFrEF centers on four foundational drug classes, all with Class I recommendations for reducing mortality and hospitalizations:

1. Renin-Angiotensin System Inhibition

• First-line: ARNI (Sacubitril-Valsartan)

  • Start: 24/26 mg or 49/51 mg twice daily
  • Target: 97/103 mg twice daily 3
  • Superior to ACE inhibitors for reducing HF hospitalization and death 3

• Alternative: ACE Inhibitors (if ARNI not tolerated)

  • Always combine with beta-blocker and diuretics 4
  • Start low dose, uptitrate to target doses proven in trials 4
  • Monitor BP, renal function, and electrolytes at 1-2 weeks after each dose increase, then at 3 months, then every 6 months 4

• ARBs (candesartan 4-8 mg daily, target 32 mg daily) are reserved for patients intolerant to both ARNI and ACE inhibitors 3

2. Beta-Blockers

Only use evidence-based agents: carvedilol, metoprolol succinate, or bisoprolol 4, 3

• Recommended for all stable HFrEF patients (NYHA II-IV) on standard therapy 4
• Reduce mortality by at least 20% 5
• Reduce sudden cardiac death risk 5
• Initiate at low doses and force-titrate to target doses used in landmark trials 5

3. Mineralocorticoid Receptor Antagonists

• Spironolactone: Start 12.5-25 mg daily, target 25-50 mg daily 3
• Eplerenone: Start 25 mg daily, target 50 mg daily 3
• Recommended for patients remaining symptomatic despite ACE inhibitor and beta-blocker 4, 3
• Particularly indicated in advanced HF (NYHA III-IV) to improve survival 4
• Check potassium and creatinine after 5-7 days, recheck every 5-7 days until stable 4

4. SGLT2 Inhibitors (Newest Pillar)

• Dapagliflozin: 10 mg daily 6, 1, 2
• Empagliflozin: 10 mg daily (can increase to 25 mg) 6
• Benefits emerge within weeks of initiation 7
• Effective regardless of diabetes status 1, 2

Implementation Strategy: "Four Drugs in 4 Weeks"

The evidence supports rapid, simultaneous initiation rather than sequential addition 8, 7, 9:

1. Week 1: Initiate all four pillars at starting doses simultaneously
2. Weeks 2-6: Uptitrate each medication toward target doses
3. By 6-12 weeks: Achieve target doses unless intolerance documented 1, 2, 10

Recent data shows that early quadruple therapy initiation (within 6 weeks) and higher 6-month doses correlate with greater LVEF improvement and better outcomes 9.

Diuretics (Symptomatic Relief)

Loop diuretics or thiazides are always administered in addition to the four pillars 4:

• Use for congestion symptoms only (not mortality benefit) 3
• If GFR <30 ml/min: avoid thiazides except synergistically with loop diuretics 4
• For insufficient response: increase dose, combine loop diuretics with thiazides, or administer loop diuretics twice daily 4
• In severe chronic HF with persistent fluid retention: add metolazone with frequent creatinine/electrolyte monitoring 4

Additional Therapies for Specific Situations

Digoxin

• For atrial fibrillation with any degree of symptomatic HF to slow ventricular rate 4
• In sinus rhythm: only for persistent symptoms despite optimal therapy 4
• Usual dose: 0.25-0.375 mg daily (0.125-0.25 mg in elderly) if normal renal function 4
• Combination with beta-blocker superior to either alone 4

Critical Implementation Points

Forced-Titration Strategy

The landmark trials used aggressive uptitration protocols 5:

• Start low, increase doses at specific intervals
• Target doses are the same for every patient
• Temporary dose reductions are acceptable, but reinstitute and achieve targets
• Asymptomatic vital sign or lab changes should NOT prevent uptitration 5
• Only maintain subtarget doses if higher doses threaten clinical stability 5

Common Pitfalls to Avoid

• Do NOT use diltiazem or verapamil - they increase HF worsening and hospitalization (Class III) 3
• Do NOT combine ARB with ACE inhibitor AND MRA - increased risk of renal dysfunction and hyperkalemia (Class III) 3
• Avoid NSAIDs - interfere with ACE inhibitor efficacy 4
• Avoid potassium-sparing diuretics during ACE inhibitor initiation 4
• Do NOT maintain patients on starting doses indefinitely - this is the most common real-world failure 5

Monitoring Requirements

• BP, renal function, electrolytes: 1-2 weeks after each dose increment, at 3 months, then every 6 months 4
• If renal function deteriorates substantially: stop ACE inhibitor 4
• For MRA: check potassium/creatinine after 5-7 days, recheck every 5-7 days until stable 4

Device Therapy Considerations

ICD for primary prevention is recommended when 3:

• Symptomatic HF (NYHA II-III)
• LVEF ≤35% despite ≥3 months of optimal medical therapy
• Expected survival >1 year with good functional status
• Ischemic heart disease (not within 40 days of MI) or dilated cardiomyopathy

Real-World Implementation Gap

Despite strong evidence, real-world data shows persistent underutilization 11, 12, 9:

• Only 20-47% of patients receive quadruple therapy 11, 12, 9
• ARNI use remains particularly low (0-22%) 11, 12
• Most patients remain on starting doses rather than target doses 5

The priority is achieving target doses of all four pillars through forced-titration strategies, as this is what the mortality and morbidity benefits are based upon 5.